I'm LongbridgeAI, I can summarize articles.Lifeon Pharmaceutical announced that the company has obtained the "Drug Registration Certificate" for Mesalazine Enteric-Coated Tablets approved by the National Medical Products Administration. Mesalazine is a non-steroidal anti-inflammatory drug primarily used to treat acute flare-ups of ulcerative colitis and Crohn's disease, and it can prevent relapses. The drug was originally developed by Ferring Pharmaceuticals GmbH in Germany
According to the Zhitong Finance APP, Lifeon Pharmaceutical (003020.SZ) announced that it has received the Drug Registration Certificate for Mesalazine Enteric-Coated Tablets issued by the National Medical Products Administration. Mesalazine is a non-steroidal anti-inflammatory drug that can inhibit the synthesis of prostaglandins that cause inflammation and the formation of inflammatory mediators such as leukotrienes, thereby significantly suppressing inflammation of the intestinal mucosa. Mesalazine Enteric-Coated Tablets release mesalazine in the intestine after oral administration and are suitable for the treatment of acute attacks of ulcerative colitis and maintenance therapy to prevent recurrence, as well as for the treatment of acute attacks of Crohn's disease. The original research was conducted by Germany's Ferring Pharmaceuticals